Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

6

US Previously Marketed

5

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

NADH-cytochrome b5 reductase 3

6

Nitric oxide synthase (inducible and endothelial)

6

DNA

5

Endothelial PAS domain-containing protein 1

5

Hypoxia-inducible factor 1 alpha

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1919

5

1921

6

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Alzheimer’s disease

6

Cancer

6

Dermatologic infections

6

Ifosfamide-induced encelophaty

6

Methemoglobinemia

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

11

Diagnostic

6

Preventing

6

Curative

5

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

11

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

BASF

6

Ehrlich, P.

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

9

Mixture

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

11

FDA UNII

11

PUBCHEM

9

EPA CompTox

8

CHEBI

7

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

RESPIRATORY SYSTEM

2

VARIOUS

2

DERMATOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ALL OTHER THERAPEUTIC PRODUCTS

2

DIAGNOSTIC AGENTS

2

THROAT PREPARATIONS

2

ANTISEPTICS AND DISINFECTANTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ALL OTHER THERAPEUTIC PRODUCTS

2

OTHER DIAGNOSTIC AGENTS

2

THROAT PREPARATIONS

2

ANTISEPTICS AND DISINFECTANTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antidotes

2

Antiseptics

2

Tests for gastric secretion

2

Acridine derivatives

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

9

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 11 results

First page disabled
Previous page disabled
1
Next page
Next page

METHYLENE BLUE CATION

ZMZ79891ZH

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

NADH-cytochrome b5 reductase 3

Nitric oxide synthase (inducible and endothelial)

Conditions:

Ifosfamide-induced encelophaty

Methemoglobinemia

Dermatologic infections

Alzheimer’s disease

Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. ...

Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease.

ACRIFLAVINE

1T3A50395T

Status:

US Previously Marketed

First marketed in 1919

Class:

MIXTURE

Targets:

Hypoxia-inducible factor 1 alpha

Endothelial PAS domain-containing protein 1

Conditions:

Prostate cancer

Acriflavine (ACF) is a topical antiseptic. The hydrochloride form is more irritating than the neutral form. It is derived from acridine. Commercial preparations are often mixtures with proflavine. Acriflavine was developed in 1912 by Paul Ehrlich, a ...

German medical researcher, and was used during the First World War against sleeping sickness. ACF has known trypanocidal, antibacterial, and antiviral activities. Effects of ACF on cancer cells were first reported 50 years ago. By present time was demonstrated that ACF a drug, that binds directly to HIF-1 alpha and HIF-2 alpha and inhibits HIF-1 dimerization and transcriptional activity and thus has potent inhibitory effects on tumor growth and vascularization. Also Acriflavine in combination with 3,6-diaminoacridine (proflavine) could prove to be a potential antimalarial drug and its pharmacological action can be due to inhibition of gyrase activity. This is achieved through interaction of the ACF with the DNA substrate. This interaction may lead to conformation change in DNA unsuitable for binding of gyrase with DNA.

METHYLENE BLUE PENTAHYDRATE

TJ8EMU6QT3

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

NADH-cytochrome b5 reductase 3

Nitric oxide synthase (inducible and endothelial)

Conditions:

Ifosfamide-induced encelophaty

Methemoglobinemia

Dermatologic infections

Alzheimer’s disease

Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. ...

Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease.

METHYLENE BLUE MONOHYDRATE

O3YJW1TB3C

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

NADH-cytochrome b5 reductase 3

Nitric oxide synthase (inducible and endothelial)

Conditions:

Ifosfamide-induced encelophaty

Methemoglobinemia

Dermatologic infections

Alzheimer’s disease

Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. ...

Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease.

METHYLENE BLUE HYDROXIDE

3EAZ4M2MHL

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

NADH-cytochrome b5 reductase 3

Nitric oxide synthase (inducible and endothelial)

Conditions:

Ifosfamide-induced encelophaty

Methemoglobinemia

Dermatologic infections

Alzheimer’s disease

Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. ...

Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease.

METHYLENE BLUE ANHYDROUS

8NAP7826UB

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

NADH-cytochrome b5 reductase 3

Nitric oxide synthase (inducible and endothelial)

Conditions:

Ifosfamide-induced encelophaty

Methemoglobinemia

Dermatologic infections

Alzheimer’s disease

Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. ...

Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease.

METHYLENE BLUE

T42P99266K

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

NADH-cytochrome b5 reductase 3

Nitric oxide synthase (inducible and endothelial)

Conditions:

Ifosfamide-induced encelophaty

Methemoglobinemia

Dermatologic infections

Alzheimer’s disease

Methylene blue, also known as methylthioninium chloride, is a medication from WHO's list of essential medicines. Upon administration, methylene blue is converted to leukomethylene blue by erythrocyte methemoblobin reductase in the presence of NADPH. ...

Leukomethylene blue than reduces methemoglobin to oxyhemoglobin, thus restoring oxygen carrying capacity of the blood. Methylene blue is also used as a dye for various diagnostic procedures, for treatment of ifosfamide toxicity and for in vitro staining. Historically, it was used as a photosensitizer for photodynamic therapy for topical treatment of dermatologic or mucocutaneous infections, as an antidote for cyanide poisoning, but these applications are no longer approved. Methylene blue is investigated in clinical trials for treatment of septic shock and Alzheimer's disease.

3,6-Diamino-10-methylacridinium

J276XBF77Z

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1919

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hypoxia-inducible factor 1 alpha

Endothelial PAS domain-containing protein 1

Conditions:

Prostate cancer

Acriflavine (ACF) is a topical antiseptic. The hydrochloride form is more irritating than the neutral form. It is derived from acridine. Commercial preparations are often mixtures with proflavine. Acriflavine was developed in 1912 by Paul Ehrlich, a ...

German medical researcher, and was used during the First World War against sleeping sickness. ACF has known trypanocidal, antibacterial, and antiviral activities. Effects of ACF on cancer cells were first reported 50 years ago. By present time was demonstrated that ACF a drug, that binds directly to HIF-1 alpha and HIF-2 alpha and inhibits HIF-1 dimerization and transcriptional activity and thus has potent inhibitory effects on tumor growth and vascularization. Also Acriflavine in combination with 3,6-diaminoacridine (proflavine) could prove to be a potential antimalarial drug and its pharmacological action can be due to inhibition of gyrase activity. This is achieved through interaction of the ACF with the DNA substrate. This interaction may lead to conformation change in DNA unsuitable for binding of gyrase with DNA.

3,6-DIAMINO-10-METHYLACRIDINIUM CHLORIDE HYDROCHLORIDE

0596YAL51J

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1919

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hypoxia-inducible factor 1 alpha

Endothelial PAS domain-containing protein 1

Conditions:

Prostate cancer

Acriflavine (ACF) is a topical antiseptic. The hydrochloride form is more irritating than the neutral form. It is derived from acridine. Commercial preparations are often mixtures with proflavine. Acriflavine was developed in 1912 by Paul Ehrlich, a ...

German medical researcher, and was used during the First World War against sleeping sickness. ACF has known trypanocidal, antibacterial, and antiviral activities. Effects of ACF on cancer cells were first reported 50 years ago. By present time was demonstrated that ACF a drug, that binds directly to HIF-1 alpha and HIF-2 alpha and inhibits HIF-1 dimerization and transcriptional activity and thus has potent inhibitory effects on tumor growth and vascularization. Also Acriflavine in combination with 3,6-diaminoacridine (proflavine) could prove to be a potential antimalarial drug and its pharmacological action can be due to inhibition of gyrase activity. This is achieved through interaction of the ACF with the DNA substrate. This interaction may lead to conformation change in DNA unsuitable for binding of gyrase with DNA.

3,6-DIAMINO-10-METHYLACRIDINIUM CHLORIDE

1TW3Q60E36

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1919

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hypoxia-inducible factor 1 alpha

Endothelial PAS domain-containing protein 1

Conditions:

Prostate cancer

Acriflavine (ACF) is a topical antiseptic. The hydrochloride form is more irritating than the neutral form. It is derived from acridine. Commercial preparations are often mixtures with proflavine. Acriflavine was developed in 1912 by Paul Ehrlich, a ...

German medical researcher, and was used during the First World War against sleeping sickness. ACF has known trypanocidal, antibacterial, and antiviral activities. Effects of ACF on cancer cells were first reported 50 years ago. By present time was demonstrated that ACF a drug, that binds directly to HIF-1 alpha and HIF-2 alpha and inhibits HIF-1 dimerization and transcriptional activity and thus has potent inhibitory effects on tumor growth and vascularization. Also Acriflavine in combination with 3,6-diaminoacridine (proflavine) could prove to be a potential antimalarial drug and its pharmacological action can be due to inhibition of gyrase activity. This is achieved through interaction of the ACF with the DNA substrate. This interaction may lead to conformation change in DNA unsuitable for binding of gyrase with DNA.

Showing 1 - 10 of 11 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1